ALBANY, N.Y., March 11, 2016 /PRNewswire/ -- AMRI (NASDAQ: AMRI) today announced that it has filed with the U.S. Securities and Exchange Commission (SEC) a Form 12b-25 Notification of Late Filing with regard to its Annual Report on Form 10-K for the year ended December 31, 2015 to finalize its consolidated financial statements due to greater complexity connected with the Company's four acquisitions in 2015. The Company expects such consolidated financial statements will be consistent with the results of operations discussed in a press release issued on February 17, 2016.
"We completed four significant acquisitions in 2015, following two others in 2014," said William S. Marth, AMRI's president and chief executive officer. "These transformative additions have greatly expanded our capabilities and revenue base, and have also added to the complexity of our financial reporting. We have increased our internal financial and accounting staffing and we are working to complete all remaining matters and expect to file our Form 10-K no later than March 30, 2016."
Albany Molecular Research Inc. (AMRI) is a global contract research and manufacturing organization that has been working with the Life Sciences industry to improve patient outcomes and the quality of life for more than two decades. With locations in North America, Europe and Asia, our key business segments include Discovery and Development Services (DDS), Active Pharmaceutical Ingredients (API), and Drug Product Manufacturing (DPM). Our DDS segment provides comprehensive services from hit identification to IND, including expertise with diverse chemistry, library design and synthesis, in vitro biology and pharmacology, drug metabolism and pharmacokinetics, as well as natural products. API supports the chemical development and cGMP manufacture of complex API, including potent and cytotoxic compounds, controlled substances, steroids, peptides, hormones, and sterile API. DPM supports development through commercial scale production of complex liquid-filled and lyophilized parenterals, sterile suspensions and ophthalmic formulations. For more information about AMRI, please visit our website at www.amriglobal.com or follow us on Twitter (@amriglobal).
This press release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that involve risks and uncertainties. These statements include, but are not limited to, statements concerning the timing of the filing of the Company's Annual Report on Form 10-K for the year ended December 31, 2015 and statements regarding the effects of the Company's business acquisitions. Readers should not place undue reliance on our forward-looking statements. The Company's actual results may differ materially from such forward-looking statements as a result of numerous factors, some of which the Company may not be able to predict and may not be within the Company's control. Factors that could cause such differences include, but are not limited to, the ability of the Company to finalize its consolidated financial statements and realize the expected financial contributions of the acquired businesses, as well as those risks discussed in the Company's Annual Report on Form 10-K for the year ended December 31, 2014 as filed with the Securities and Exchange Commission on March 16, 2015, and the Company's other SEC filings. If the Company's 2015 results of operations are not consistent with the results of operations disclosed in the Company's earnings press release issued on February 17, 2016, the Company's stock price could decline.